Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals is a patient-centric, clinical-stage biopharmaceutical company dedicated to developing treatments for episodic cardiovascular conditions such as paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). The company focuses on self-administration treatments that can be used outside of emergency or hospital settings, aiming to fill unmet medical needs and improve patient quality of life. Their lead investigational product, etripamil, is a nasal spray calcium channel blocker designed for rapid, at-home treatment of these conditions. Milestone is committed to advancing scientific discovery through clinical trials and research, with a mission to empower patients to manage their episodes wherever and whenever they occur.
Industries
Nr. of Employees
small (1-50)
Milestone Pharmaceuticals Inc.
1111, boul. Frederik-Philips, bureau 420, Montréal (Québec) H4M 2X6 Canada
Patents
Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
US-12257224-B2
View DetailsHighly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
US-10117848-B2
View Details
Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
US-12257224-B2
View DetailsHighly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
US-10117848-B2
View DetailsProducts
Investigational intranasal small-molecule calcium channel blocker for at-home acute treatment of episodic cardiovascular events
An investigational, intranasally administered small-molecule calcium channel blocker developed for rapid, outpatient self-administration to terminate paroxysmal supraventricular tachycardia (PSVT) and to control atrial fibrillation with rapid ventricular rate (AFib-RVR). Not approved for any indication.
Investigational intranasal small-molecule calcium channel blocker for at-home acute treatment of episodic cardiovascular events
An investigational, intranasally administered small-molecule calcium channel blocker developed for rapid, outpatient self-administration to terminate paroxysmal supraventricular tachycardia (PSVT) and to control atrial fibrillation with rapid ventricular rate (AFib-RVR). Not approved for any indication.
Services
Management of clinical studies for acute, episodic cardiovascular conditions and programs to support patient recruitment and trial participation.
Creation and operation of condition-specific patient resources and educational websites to support disease management and trial awareness.
Management of clinical studies for acute, episodic cardiovascular conditions and programs to support patient recruitment and trial participation.
Creation and operation of condition-specific patient resources and educational websites to support disease management and trial awareness.
Expertise Areas
- Clinical trial management for cardiovascular indications
- Small-molecule drug discovery and optimization
- Intranasal drug delivery and formulation
- Regulatory submission & health authority interactions
Key Technologies
- Intranasal drug delivery
- Small-molecule calcium channel blockade (mechanism-driven design)
- Rapid-onset, short half-life pharmacokinetic profiles
- Phase 2–3 clinical development
News & Updates
This study utilized claims data from both Medicare and private insurers to estimate the treated prevalence and incidence of PSVT in the U.S. over a nine-year period.
This study utilized claims data from both Medicare and private insurers to estimate the treated prevalence and incidence of PSVT in the U.S. over a nine-year period.